Universitaetsklinikum Schleswig-Holstein
Also known as: Chair of the Dept. of Anaesthesiology and Intensive Care Medicine, University of Schleswig-Holstein Campus Kiel | Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein, Campus Kiel | Consultant in Anesthesiology, Dep. of Anesthesiology and Intenisve Care Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Germany | Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Kiel | Martin Schrappe | Neurological pain research and therapy Clinic for Neurology Campus Kiel, University Clinic Schleswig-Holstein, Schittenhelmstr. 10, 24105 Kiel, Germany | Prof. Dr. Stephan Weidinger | Universitaetsklinikum Schleswig-Holstein - Campus Luebeck | University Clinic Schleswig-Holstein | University Hopsital Schleswig Holstein Campus Lübeck | University Hospital of Schleswig-Holstein | University Hospital Schleswig-Holstein | University Hospital Schleswig-Holstein, 24105 Kiel, Germany | University Hospital Schleswig-Holstein, Campus Kiel | University Hospital Schleswig-Holstein, Campus Kiel, Department of Anaesthesiology and Intensive Care Medicine | University hospital Schleswig-Holstein, Germany | University Medical Center Schleswig-Holstein, Campus Kiel | University Medical Center, Schleswig-Holstein, Department of Dermatology, Schittenhelmstr. 7, 24105 Kiel, Germany | University of Scghleswig-Holstein, Campus Kiel, Department of Nephrology | University of Schleswig-Holstein | University of Schleswig-Holstein, campus Kiel Department odf Nephrology | University of Schleswig-Holstein, Campus Kiel Department of Nephrolgy | University of Schleswig-Holstein, Campus Kiel Department of Nephrology | University of Schleswig-Holstein, Campus Kiel, Department of Nephrology
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2003Last known activity
Jan 1, 2026
Timeline
2000s
- Jan 1, 2003
Universitaetsklinikum Schleswig-Holstein— Founded
Drugs by trial phase (90 distinct, 54 trials)
Phase 4 (10 own, 0 via acquisition)
Phase 3 (40 own, 0 via acquisition)
Phase 2 (17 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Back Pain
- Cadaver
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Churg-Strauss Syndrome
- Colitis
- Colitis, Ulcerative
- Colorectal Neoplasms
- Dermatitis
- Dermatitis, Atopic
- Eczema
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Genital Neoplasms, Female
- Hyperalgesia
- Kidney Neoplasms
- Leukemia
- Leukemia, Large Granular Lymphocytic
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Low Back Pain
- Melanoma
- Neuralgia
- Pancreatic Neoplasms
- Peripheral Nervous System Diseases
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Psoriasis
- Respiratory Aspiration
- Rosacea
- Sarcoma
- Syndrome
- Thyroid Diseases
- Thyroid Neoplasms
- Ulcer
- Ureteral Neoplasms
- Urethral Neoplasms
- Urinary Bladder Neoplasms
- Vomiting
Recent trials (50)
- NCT07286747OfficialPhase 2Jan 1, 2026
- NCT07286747Lead sponsorPhase 2Jan 1, 2026
- NCT07235904Lead sponsorPhase 4Nov 30, 2025
- NCT06488625Lead sponsorPhase 2/Phase 3Sep 12, 2024
- NCT07156929Lead sponsorN/AApr 20, 2024
- NCT07156929OfficialN/AApr 20, 2024
- NCT06279793CollaboratorPhase 2Feb 15, 2024
- NCT06097533Lead sponsorPhase 2/Phase 3Dec 1, 2023
- NCT05665140Lead sponsorPhase 2/Phase 3Jan 31, 2023
- NCT05665140Sponsor investigatorPhase 2/Phase 3Jan 31, 2023
- NCT05665140Reponsible party - principal investigatorPhase 2/Phase 3Jan 31, 2023
- NCT06378125OfficialPhase 1Dec 19, 2022
- NCT06378125Lead sponsorPhase 1Dec 19, 2022
- NCT05638633CollaboratorPhase 3Nov 11, 2022
- NCT05182385CollaboratorPhase 1/Phase 2Dec 15, 2021
Details
- Founded
- DE Jan 1, 2003
- Last known activity
- Jan 1, 2026
Notes
--- Pre-folding founded info: None None None None None ---